Shanghai Location

Our Shanghai team specializes in preclinical pharmaceutical development offering a variety of options for study and molecule types, as well as capacity to accommodate fast and flexible study starts. From Biologics to Immunotoxicology & Immunology to IND-enabling, our global data approach ensures dependable delivery.

Recent Investments & Expansions

Now offering the following enhancements:

  • 2X more large animal capacity for fast and flexible study starts
  • Options for EU-compliant housing
  • Full-service IND-enabling packages for Biologics
  • New Immunotoxicology & immunology and cell culture laboratories
  • Disease model testing for COPD, IBD, Tumor xenografts, NASH, hepatitis and fibrosis
  • Connected scientific and regulatory expertise enabling dual filing in the U.S. and China and large molecule IND-enabling studies
Covance facility

Gross Ft2: 85,000 +

No. of Study Rooms: 45+

No. of PhDs: 5+

Total Employment: 140+

Site Stats


Specialized Expertise

  • Preclinical and clinical pharmaceutical development


  • AAALAC accredited
  • Animal housing compliant with the Guide to the Care and Use of Laboratory Animals, 8th edition
  • Good Laboratory Practice (GLP) Certification from the NMPA of the People's Republic of China and the OECD. Inspected by the US FDA

Dose Routes

  • Dermal
  • IV infusion
  • Oral: capsule, gavage
  • Parenteral (IM, SC, IV)

The Shanghai R&D Center

The Shanghai R&D Center combines bioanalytical, clinical trial testing and clinical development operations in one convenient location. This experienced team has more than 20 years of experience with Chinese regulations and drug development best-practices.